Our Science
Approximately 90% of disease-causing proteins are not drugged, or are inadequately drugged, due to limitations with traditional small molecules that target the active site of a protein.
Allostery holds the key to drugging the 90% of disease-causing proteins that have remained intractable.
Atavistik Bio is developing selective allosteric therapeutics that have the potential to transform the lives of patients with significant unmet medical need.
———
Leveraging Allostery to Drug the Undruggable
We are harnessing the power of allostery to address unmet patient needs.
Allostery holds the potential to drug intractable targets.
Our platform leverages inherent allosteric activity of endogenous metabolites to enable rapid ID of functional binders to biologically relevant pockets.
The identification of allosteric pockets fast-tracks discovery of exquisitely selective and highly potent small molecule therapeutics.
By leveraging the body’s natural regulators, we efficiently and systematically uncover functional allosteric pockets across a broad range of target classes (e.g., transcription factors, membrane proteins, large complexes).
Our Platform
AMPS Screening Technology Repeatedly Identifies Functional Binders for Novel Allosteric Drug Discovery
 |
 |
 |
|
 |
| AMPS library and screening empirically leads to identification of functional allosteric binders | Novel cryptic binding pockets enable rapid and efficient AI/ML driven structure-based drug design and chemistry | Structure-based drug design supports rapid improvements in potency to generate differentiated therapeutics |
Therapeutic Approach
We have successfully adapted our platform to screen and identify functional pockets on a broad range of protein classes. While our internal pipeline is focused on rare hematology, the versatility of our platform allows us to accelerate the development of groundbreaking medicines across any therapeutic area.
We plan to unlock the potential of our platform in other therapeutic areas through strategic partnerships. By combining the disease specific insights of our partners with the capabilities here at Atavistik, we hope to advance transformative therapies in a broad range of therapeutic areas.